Trials / Completed
CompletedNCT03128320
The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure
A Randomized, Single-blind, Threefold Crossover, Single-center Study to Assess the Safety and the Effects of 1 mg and 5 mg BAY1193397 in Comparison to Placebo on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure After Single Dose in Type II Diabetic Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 55 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to analyse skin blood flow in diabetic patients. The patients receive a single dose of placebo, 1 mg BAY1193397, and 5 mg BAY1193397. The analysis of safety and tolerability are secondary objectives of this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY1193397 | Single dose of 1 mg BAY1193397 given in the fasted state |
| DRUG | BAY1193397 | Single dose of 5 mg BAY1193397 given in the fasted state |
| DRUG | Placebo | Single dose of placebo given in the fasted state |
Timeline
- Start date
- 2017-05-25
- Primary completion
- 2019-09-06
- Completion
- 2019-10-28
- First posted
- 2017-04-25
- Last updated
- 2020-08-13
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03128320. Inclusion in this directory is not an endorsement.